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ABSTRACT
Introduction. Contraception is a critical component of addressing 
the health needs of women in the postpartum period. We assessed 
contraception initiation by 90 days postpartum at a large, academic 
medical center in the Midwest.
Methods.xIn this retrospective cohort study, 299 charts were ran-
domly sampled and 231 were analyzed from deliveries between May 
1 to July 5, 2018. Contraceptive method, maternal demographics, and 
obstetric characteristics at hospital discharge were collected, as well 
as contraceptive method at the postpartum follow-up appointment. 
Methods and strata of contraception were categorized as follows: 1) 
highly effective methods (HEM) defined as sterilization, intrauterine 
device, or implant, 2) moderately effective methods (MEM) defined 
as injectable contraception, progestin-only pills, and combined estro-
gen/progestin pills, patches, and rings, and 3) less effective methods 
(LEM) defined as condoms, natural family planning, and lactational 
amenorrhea. Women lost to follow-up who had initiated a HEM or 
injectable contraception were coded as still using the method at 90 
days. We used logistic regression to identity factors associated with 
HEM use.
Results. Of the 231 included patients, 118 (51%) received contracep-
tion before hospital discharge and 166 (83%) by 90 days postpartum. 
Postpartum visits were attended by 74% (171/231) of patients. Before 
hospital discharge, 28% (65/231) obtained a HEM and 41% (82/200) 
were using a HEM by 90 days postpartum. Patients obtaining HEM 
or injectable contraception before hospital discharge attended a fol-
low-up visit less often than those who did not receive HEM before 
discharge (RR = 0.68, 95% CI: 0.54 - 0.86, p ≤ 0.01).
Conclusion. When readily available, many women will initiate con-
traception in the postpartum period. Health systems should work 
to ensure comprehensive access to contraception for women in the 
postpartum period. Kans J Med 2020;13:202-208
INTRODUCTION
The postpartum period represents a time for clinicians to provide 
ongoing care that assesses many facets of women’s health and 
well-being, setting the stage for long-term wellness.1 Postpartum 
contraception is one critical component in addressing the health 
needs of women and their families. Between 16 - 36% of women do 
not attend the six-week follow-up appointment, which may be influ-
enced by insurance type or mode of delivery.2  Ensuring early and 
available postpartum contraception meets patients’ needs because 
40 - 57% of women report having unprotected intercourse before 
the standard six-week postpartum visit.3 Additionally, half of the 3.2 
million annual unintended pregnancies occur within 18 months of a 
prior live birth.4-6 
By 18 months postpartum, the estimated pregnancy probability 
while using hormonal contraception is 17%.5 Effective contraception 
use decreases pregnancy risk; sterilization and long-acting reversible 
contraception (LARC), which includes intrauterine devices (IUDs) 
and implants, decreases the chances of pregnancy to 0.5% annually.5,7 
Less effective methods, including male condoms and withdrawal, 
have a higher probability of pregnancy annually, from 18 - 28%.5,8 In 
some settings, women can obtain immediate LARCs before hospital 
discharge, yet this option for contraception delivery has not been 
implemented fully across the country, including parts of Kansas. In 
one study of over 8,000 postpartum women at a single institution, 
less than one in four women who expressed interest in LARCs at 
the time of hospital discharge successfully obtained one by 90 days 
postpartum.9 States have been working to improve access to immedi-
ate postpartum contraception, including LARC.10-12  In May 2018, a 
policy change was made for Kansas Medicaid to reimburse immedi-
ate postpartum LARC. In this study, the incidence of contraception 
use at hospital discharge and by 90 days postpartum was described, 
as well as the types of contraception used.
METHODS
Data Source and Sample Description. A retrospective cohort 
study was conducted for women who delivered at the University of 
Kansas Hospital (UKH) from May 1, 2018 to July 5, 2018. While 
UKH already had LARCs (including the copper IUD, 13.5-mg 
levonorgestrel IUD, 52-mg levonorgestrel IUD, and 68-mg etono-
gestrel implant) available on the inpatient formulary, reimbursement 
concerns limited their use in the immediate postpartum period. 
Therefore, the time period after the policy change was chosen to 
describe the use of postpartum contraception after the policy imple-
mentation.
Data were extracted from the Healthcare Enterprise Repository 
for Ontological Narration (HERON) discovery tool that can search 
de-identified data from the electronic medical records available 
at UKH and provide researchers with an identifiable dataset with 
appropriate human subjects training and approval.13 The HERON 
search discovery tool identified the cohort of women over 18 years of 
age who delivered at UKH during the study time frame. Women were 
excluded who planned to follow-up outside of UKH (as documented 
in delivery discharge summaries), because their postpartum medical 
records would not be accessible. The Institutional Review Board at 
UKH approved this study.
A sample size of 198 participants was calculated, based on an 
estimated incidence of 47% (± 5%) contraception use at 90-days 
postpartum and an alpha of 0.05.5,9 A random sample of 299 charts 
was reviewed to account for patients who would be excluded or lost 
to follow-up by 90 days. Each patient’s chart was reviewed by one of 
six fourth-year medical students trained in chart abstraction. Data 
were managed and collected using REDCap electronic data capture 
tools hosted at our institution.14,15
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Measures. Basic demographic data and obstetric history were col-
lected for each patient, including maternal age, race, marital status, 
primary language, insurance, gravidity, and parity. Information also 
was collected about the patient’s pregnancy and delivery,  including: 1) 
the trimester of prenatal care initiation (first trimester defined as less 
than 14 weeks and second trimester defined as less than 28 weeks), 
2) whether they were followed in the High Risk Clinic (defined by 
more than one consult visit), 3) the presence of multiple gestations, 
4) the admitting department as either  Obstetrics (including certified 
nurse-midwives) or Family Practice, 5) type of delivery (cesarean 
or vaginal), and 6) documentation of scheduled follow-up appoint-
ment at time of hospital discharge. Pregnancy history was obtained 
from documentation in outpatient clinic notes and/or the admission 
history and physical note. The delivery type, contraception methods, 
and postpartum visit data were collected from documentation in pro-
cedural notes, discharge summaries, and outpatient clinic notes.
The type of contraception documented in procedure notes or 
discharge summary was recorded. Following previous studies16,17, 
contraceptive methods were defined as: 1) self or partner surgical 
sterilization (as verified by review of operative report or documenta-
tion of patient or partner’s completed sterilization), 2) intrauterine 
devices, 3) subdermal implants, 4) injectable contraception, 5) com-
bined estrogen/progestin pills, patches, and rings, 6) progestin-only 
pills, 7) condoms, 8) natural family planning, 9) lactational amenor-
rhea, 10) no birth control (verified in the medical record as “declines 
contraception”), and 11) not documented. Contraceptive types were 
stratified into three groups similar to previous studies18: highly effec-
tive methods (HEM): methods 1 - 3, moderately effective methods 
(MEM): methods 4 - 6, and less effective methods (LEM): methods 
7 - 9. 
Whether the patient returned for a postpartum follow-up visit was 
documented and the number of days between discharge and the first 
follow-up in the 90-day postpartum period was recorded.  If a patient 
returned for a postpartum visit, the type of contraception documented 
in the first follow-up visit was noted. Patients without a follow-up visit 
that had received sterilization, LARC, or injectable contraception at 
the time of hospital discharge were recorded as using that method of 
contraception at the end of the 90-day period, because the method 
efficacy continues through 90 days. Patients were excluded who did 
not attend a postpartum visit without documentation of sterilization, 
LARC, or injectable contraception at hospital discharge from the 
90-day analysis.
Statistical Analysis. Baseline characteristics were summarized 
for all women included in our study using descriptive statistics. The 
proportion of women who returned for a follow-up visit within 90 
days were calculated. The median time to follow-up was recorded in 
days. The relative risk of attending follow-up was calculated for those 
who had HEM documented at discharge compared to those who did 
not. While providers at UKH typically recommended a postpartum 
visit at six weeks, the follow-up window was expanded to 90 days, 
reflecting previous studies on postpartum contraception.5,9  To evalu-
ate contraceptive initiation in the hospital, the type of contraception 
documented for all women before hospital discharge was recorded. 
To evaluate contraception use by 90 days, the type of contraception 
for women who attended a follow-up visit or had documentation of 
HEM or injectable contraception at discharge was recorded.      
To assess characteristics associated with HEM use, the type of 
contraception used was reduced into HEM versus other for both 
hospital discharge and 90-day follow-up data. Binary logistic regres-
sion was performed with the following factors: maternal age, race, 
marital status, insurance type, gravidity, a short interpregnancy inter-
val (defined as a conception within 18 months of delivery), timing of 
prenatal care, high risk pregnancy, hospital admitting service, delivery 
method, whether the patient had a follow-up appointment scheduled 
at discharge, and method of contraception at time of discharge. Any 
factors significant at the α = 0.05 level in the bivariate analysis were 
added to a multivariable model.   
For all statistical analysis a p value less 0.05 was considered signifi-
cant. All statistical analysis was performed with SAS software version 
9.4 (SAS Institute, Inc., Cary, NC).19
RESULTS
The HERON discovery tool identified 407 women who delivered 
at UKH during our study time frame. A random sample of 299 charts 
were reviewed. Sixty-eight patients were excluded due to documen-
tation of planned follow-up outside the UKH. The remaining 231 
patients were included in the final analysis at hospital discharge 
(Figure 1). Most women spoke English (85%), delivered vaginally 
(75%), and had private insurance (58%; Table 1).  
Postpartum Visit Attendance. Approximately 26% (n = 60/231) 
of women did not attend a postpartum visit within 90 days. Twenty-
nine women who received HEM did not return for follow-up. These 
women were considered to have HEM at follow-up, with the excep-
tion of one woman who had documentation of an IUD expulsion. 
Thus, contraception data were available for 200 women at follow-up 
(Figure 1). The median time to follow-up was 42 days (range 5 - 88). 
Contraceptive Method Use. Before hospital discharge, 51% 
(118/231) of women had initiated a contraceptive method and 83% 
(166/200) had initiated a contraceptive method by 90 days postpar-
tum (Table 2).  Before hospital discharge, 28% (65/231) obtained a 
HEM and 41% (82/200) of patients obtained a HEM of contracep-
tion by 90 days postpartum (Table 2). Women chose sterilization 
most often at time of hospital discharge, while IUDs had the highest 
frequency of initiation by the postpartum visit (27/231, 12% and 
32/200, 16%, respectively).
Women who received HEM before discharge attended a follow-up 
visit less frequently than women who did not receive HEM (36/65, 
55% vs. 135/166, 81%, respectively; RR 0.68, 95% CI: 0.54-0.86). 
By 90 days, 56 women switched from no method to another method 
(Figure 2). The most common switch for women who were using a 
method at discharge was a switch from the progestin-only pill to the 
combined pill (n = 7). One woman experienced an IUD expulsion and 
she had another IUD inserted at her six-week postpartum appoint-
ment.
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Figure 1. Flow diagram.  
*HEM, Highly Effective Method, includes sterilization, intrauterine devices 
and contraceptive implants. 
Factors Associated with Contraceptive Method Initiation. In 
bivariate analysis, race, language spoken at home, marital status, type 
of insurance, first pregnancy, having prenatal care before 14 weeks, 
and having a high-risk pregnancy were found to be significantly asso-
ciated with use of a HEM at hospital discharge.  After adjustment in 
the multivariable model, only marital status remained a significant 
predictor of HEM use. Women who were married were less likely 
to use HEM compared to their non-married counterparts (OR 0.49, 
95%; CI 0.24-0.99, p = 0.48; Table 3). 
The bivariate analysis for use of HEM by 90 days identified 
associations between language spoken at home, marital status, first 
pregnancy, and HEM use. In the multivariable adjusted model, 
marital status and first pregnancy remained predictors of HEM use 
by 90 days (Table 4). Women who were married were less likely to 
have HEM documented by 90 days (OR 0.50; 95% CI 0.28-0.91; p = 
0.02) and women for whom this was their first pregnancy were less 
likely to have HEM documented (OR 0.44; 95% CI 0.23-0.86; p = 
0.02).
 HIGHLY EFFECTIVE POSTPARTUM CONTRACEPTION
      continued.
Table 1. Baseline characteristics (n = 231). 
Characteristic Frequency (%)
Age, years, mean (SD) 29.7 (5.75)
Race/Ethnicity
   White 110 (47.6)
   Black 49 (21.2)
   Hispanic/Latina 44 (19.0)
   Asian 12 (5.2)
   Other* 16 (6.9)
Language spoken at home
   English 197 (85.3)
   Non-English 34 (14.7)
Relationship status
   Married 119 (51.5)
   Non-married 112 (48.5)
Insurance type
   Private 134 (58.0)
   Public 76 (32.9)
   Uninsured 21 (9.1)
Gravidity, median (IQR) 2 (1-4)
Parity, median (IQR) 2 (1-3)
First pregnancy
   Yes 75 (32.5)
   No 156 (67.5)
Short interpregnancy interval†
   Yes 28 (12.1)
   No 203 (87.9)
Prenatal care before 14 weeks
   Yes 160 (69.3)
   No 71 (30.7)
High risk pregnancy care‡
   Yes 69 (29.9)
   No 162 (70.1)
Admitting service
   Obstetrics 215 (93.1)
   Family Medicine 16 (6.9)
Delivery type
   Vaginal 174 (75.3)
   Cesarean 57 (24.7)
Data are frequency (%) unless otherwise specified. SD, standard deviation; 
IQR, interquartile range.
*Includes American Indian or Alaska Native, Native Hawaiian or other Pacific 
Islander, or multiple races/ethnicities. †Conception ≤ 18 months postpartum. 
‡Defined by multiple appointments beyond one consultation visit.
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Table 2. Frequency of postpartum contraceptive methods used 
at hospital discharge and at 90 days postpartum.*
Contraceptive method
At hospital 
discharge
By 90 days 
postpartum†
n = 231 n = 200
Highly effective methods ‡
     Sterilization (self or partner) 27 11.7 31 15.5
     Intrauterine device 24 10.4 32 16.0
     Etonogestrel implant 14   6.1 19 9.5
Total 65 28.1 82 41.0
Moderately effective methods
     Injectable contraception ‡ 12   5.2 20 10.0
     Progestin-only pill 22   9.5 23 11.5
     Combined estrogen/progestin pill 0   0.0 14   7.0
     Combined estrogen/progestin ring 0   0.0 1   0.5
     Combined estrogen/progestin patch 0   0.0 0   0.0
Total 34 14.7 58 29.0
Least effective methods
     Condoms 14   6.1 15   7.5
     Natural family planning 4   1.7 9   4.5
     Lactational amenorrhea 1   0.4 2   1.0
Total 19   8.2 26 13.0
Any method of contraception 118 51.1 166 83.0
No method 113¥ 48.9 34 17.0
*Data are n (%), total %s may not add to 100 due to rounding.
†31 patients were lost to follow-up and had no documentation of a HEM or 
injectable contraception at discharge. ‡Subjects who received a highly effec-
tive method of contraceptive or injectable contraception acetate at the time 
of hospital discharge were presumed to be using this interventional method at 
90-days follow-up, unless an alternate contraceptive method was documented. 
¥5 subjects missing contraceptive method documentation were documented 
as no method.
Figure 2. Women who switched from no method of contraception at hospital 
discharge to a method of contraception by 90 days postpartum (n = 56). 
DISCUSSION
In our random sample of women delivering at a large, academic 
medical center, almost two-thirds of women had initiated a HEM 
or MEM of contraception by 90 days postpartum and almost three-
quarters attended a follow-up visit. These findings are consistent with 
previous estimates of postpartum HEM and MEM contraceptive use 
and postpartum visit attendance.2,5,20-22 
The high rates of HEM among our population may be due to a 
2018 state policy change impacting immediate postpartum LARC 
reimbursement, resulting in increased access. Previous studies have 
explored how global fees and bundled payments limit access to post-
partum contraception, particularly LARC.23,24 By increasing access 
to these methods before hospital discharge, the concern for women 
not obtaining LARCs due to loss of follow-up may be mitigated. 
This theory is supported by our finding that nearly 45% of women 
who received a HEM or injectable contraception did not attend a 
postpartum follow-up appointment. High rates of HEM use may be 
explained by our study environment: an academic teaching center 
with 24-hour anesthesia access and LARCs available on inpatient 
formulary. Notably, women without insurance can obtain both LARC 
and sterilization at our hospital, which may explain the bivariate 
finding that uninsured women-initiated HEMs of contraception at 
hospital discharge more than those with private insurance.  
Women who receive more prenatal care, as well as in women who 
received LARC-intensive or specialized family planning counseling, 
have higher rates of postpartum contraception initiation.25-27 Prenatal 
and postpartum contraception counseling appears to be a consistent 
predictor in postpartum contraception use.8,28,29 Prenatal care is also 
a positive predictor for postpartum follow-up. Women with less pre-
natal care or who begin prenatal visits later than 14 weeks gestation 
have a lower rate of postpartum follow-up.26 Public insurance status 
does not influence ability to obtain LARCs in the outpatient setting, 
but publicly-insured women miss follow-up appointments more fre-
quently, independent of social support level.26 
Our rates of postpartum follow-up were consistent with those pre-
viously reported.21,30 At UKH, women are counseled routinely about 
contraception antenatally and again at the time of hospital admission. 
Those who express interest in LARC are given the option to initiate 
the method immediately postpartum or to wait until a postpartum 
follow-up appointment. Women choosing an immediate postpartum 
LARC may have self-identified as at risk for a missed postpartum 
follow-up appointment.
Strengths of this study included a diverse population and rigorous 
assessment of contraceptive method use. The study population had a 
mix of privately-, publicly-, and uninsured women, comparable to the 
rates of public insurance coverage for births in Kansas.31 Our patients 
had high follow-up postpartum visit attendance rates, allowing for 
more complete chart review and limited missing data points. Finally, 
multivariable analysis strengthened the HEM associations. 
Our study had limitations. Our findings represented one institu-
tion, therefore, may not be generalizable to other clinical settings. Our 
inclusion criteria could bias our postpartum visit attendance results, 
since we excluded patients scheduled for care outside of UKH. Wom-
en with planned follow-up outside of UKH were all publicly insured 
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Table 3. Characteristics associated with highly effective methods (HEM)* of contraception at hospital discharge (n = 231). 
Characteristic
HEM 
(n = 65)
n (%)
Other method 
(n = 166)
n (%)
Unadjusted OR 
(95% CI) p
Adjusted OR 
(95% CI) p
Maternal age† 29.4 (6.01) 29.9 (5.66) 0.99 (0.94 - 1.04)   0.63
Race
   White 22 (20.0) 88 (80.0) 0.45 (0.25 - 0.82)   <0.01 0.94 (0.45 - 1.95) 0.87
   Other (ref) 43 (35.5) 78 (64.5)
Language
   English 48 (24.4) 149 (75.6) 0.32 (0.15 - 0.68) <0.01 0.53 (0.19 - 1.46) 0.22
   Non-English (ref) 17 (50.0) 17 (50.0)
Marital status 
   Married 22 (18.5) 97 (81.5) 0.36 (0.20 - 0.66) <0.01 0.49 (0.24 - 0.99) 0.048
   Other (ref) 43 (38.4) 69 (61.6)
Insurance
   Private 22 (16.4) 112 (83.6) 0.22 (0.08 - 0.57) <0.01 0.68 (0.17 - 2.70) 0.58
   Public 33 (43.4) 43 (56.6) 0.84 (0.32 - 2.23) 0.73 1.48 (0.48 - 4.57) 0.50
   None (ref) 10 (47.6) 11 (52.4)
First pregnancy
   Yes 11 (14.7) 64 (85.3) 0.33 (0.16 - 0.67)   <0.01 0.49 (0.23 - 1.07) 0.07
   No (ref) 27 (38.0) 44 (62.0)
Short interpregnancy interval‡
   Yes 10 (35.7) 18 (64.3) 1.50 (0.65 - 3.44)   0.34
   No (ref) 55 (27.1) 148 (72.9)
Prenatal care before 14 weeks
   Yes 38 (23.8) 122 (76.3) 0.51 (0.28 - 0.93) 0.03 1.00 (0.48 - 2.10) 0.99
   No (ref) 27 (38.0) 44 (62.0)
High risk pregnancy care§
   Yes 26 (37.7) 43 (62.3) 1.91 (1.04 - 3.50)   0.04 1.61 (0.83 - 3.12) 0.16
   No (ref) 39 (24.1) 123 (75.9)
Admitting service 
   Obstetrics 63 (29.3) 152 (70.7) 2.90 (0.64 - 13.14)   0.17
   Family Medicine (ref) 2 (12.5) 14 (87.5)
Delivery mode 
   Cesarean 19 (33.3) 38 (66.7) 1.39 (0.73 - 2.65)   0.32
   Vaginal (ref) 46 (26.4) 128 (73.6)
All characteristics with a p value < 0.05 were included in the multivariable analysis for the adjusted model. 
*HEM includes sterilization, intrauterine devices and contraceptive implants. †Mean (SD); odds of HEM per 1-year increase in age. ‡Conception ≤ 18 months 
postpartum. 
§Defined as multiple appointments beyond one consultation visit.
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or uninsured and accessed postpartum care at safety net clinics around 
the city; we could not assess their contraceptive use or follow-up rate. 
Our findings demonstrated high rates of contraception by 90 days 
postpartum in a setting with available immediate postpartum LARC. 
Ensuring comprehensive access to all methods of contraception meets 
women’s needs during the postpartum period.
KANSAS JOURNAL of  M E D I C I N E
207
HIGHLY EFFECTIVE POSTPARTUM CONTRACEPTION
continued.
Table 4. Characteristics associated with highly effective methods (HEM)* of contraception by 90 days postpartum (n = 200).
Characteristic
HEM 
(n = 82)
n (%)
Other method 
(n = 118)
n (%)
Unadjusted OR 
(95% CI) p
Adjusted OR 
(95% CI) p
Maternal age† 29.5 (5.81) 30.3 (5.42) 0.97 (0.93 - 1.03)   0.31
Race
   White 33 (35.1) 61 (64.9) 0.63 (0.36 - 1.11)   0.11
   Other (ref) 49 (46.2) 57 (53.8)
Language
   English 64 (37.9) 105 (62.1) 0.44 (0.20 - 0.96) 0.04 0.56 (0.25 - 1.25) 0.16
   Non-English (ref) 18 (58.1) 13 (41.9)
Marital status 
   Married 34 (32.4) 71 (67.6) 0.47 (0.26 - 0.83) <0.01 0.50 (0.28 -  0.91) 0.02
   Other (ref) 48 (50.5) 47 (49.5)
Insurance
   Private 35 (29.7) 83 (70.3) 0.38 (0.14 - 1.02) 0.05
   Public 37 (58.7) 26 (41.3) 1.28 (0.46 - 3.59) 0.64
   None (ref) 10 (52.6) 9 (47.4)
First pregnancy
   Yes 17 (26.2) 48 (73.9) 0.38 (0.20 - 0.73)   <0.01 0.44 (0.23 - 0.86) 0.02
   No (ref) 65 (48.2) 70 (51.9)
Short interpregnancy interval‡
   Yes 14 (58.3) 10 (41.7) 2.22 (0.94 - 5.29)   0.07
   No (ref) 68 (38.6) 108 (61.4)
Prenatal care before 14 weeks
   Yes 53 (37.3) 89 (62.7) 0.60 (0.32 - 1.10) 0.10
   No (ref) 29 (50.0) 29 (50.0)
High risk pregnancy care§
   Yes 28 (49.1) 29 (50.9) 1.60 (0.86 - 2.96)   0.14
   No (ref) 54 (37.8) 89 (62.2)
Admitting service 
   Obstetrics 75 (39.9) 113 (60.1) 0.47 (0.15 - 1.55)   0.22
   Family Medicine (ref) 7 (58.3) 5 (41.7)
Delivery mode 
   Cesarean 25 (47.2) 28 (52.8) 1.41 (0.75 - 2.66)   0.29
   Vaginal (ref) 57 (38.8) 90 (61.2)
All characteristics with a p value < 0.05 were included in the multivariable analysis for the adjusted model. 
*HEM includes sterilization, intrauterine devices and contraceptive implants. †Mean (SD); odds of HEM per 1-year increase in age. ‡Conception ≤ 18 months 
postpartum. 
§ Defined as multiple appointments beyond one consultation visit.
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